Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC, Volume 17 presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors Encompasses the current state of affairs in clinical trials to address resistance

Produk Detail:

  • Author : Anthony Faber
  • Publisher : Academic Press
  • Pages : 250 pages
  • ISBN : 9780128228333
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKOvercoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC
  • Author : Anthony Faber
  • Publisher : Academic Press
  • Release : 15 March 2021
GET THIS BOOKOvercoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC, Volume 17 presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such

Resistance to Tyrosine Kinase Inhibitors

Resistance to Tyrosine Kinase Inhibitors
  • Author : Daniele Focosi
  • Publisher : Springer
  • Release : 07 November 2016
GET THIS BOOKResistance to Tyrosine Kinase Inhibitors

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors
  • Author : Harun M. Patel,Rahul Pawara,Sanjay J. Surana
  • Publisher : Elsevier
  • Release : 27 November 2018
GET THIS BOOKThird Generation EGFR Inhibitors

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the

Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners

Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners
  • Author : Marianne Davies,Beth Eaby-Sandy
  • Publisher : Springer
  • Release : 16 July 2019
GET THIS BOOKTargeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners

This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these

Molecular Pathology of Lung Cancer

Molecular Pathology of Lung Cancer
  • Author : Philip T. Cagle,Timothy Craig Allen,Mary Beth Beasley,Lucian R. Chirieac,Sanja Dacic,Alain C. Borczuk,Keith M. Kerr
  • Publisher : Springer Science & Business Media
  • Release : 14 June 2012
GET THIS BOOKMolecular Pathology of Lung Cancer

As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related

Guide to Targeted Therapies: Treatment Resistance in Lung Cancer

Guide to Targeted Therapies: Treatment Resistance in Lung Cancer
  • Author : Federico Cappuzzo
  • Publisher : Springer
  • Release : 15 October 2015
GET THIS BOOKGuide to Targeted Therapies: Treatment Resistance in Lung Cancer

This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
  • Author : Umberto Malapelle,Pierlorenzo Pallante
  • Publisher : Frontiers Media SA
  • Release : 29 August 2017
GET THIS BOOKSecond Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and

Central Nervous System Metastases

Central Nervous System Metastases
  • Author : Manmeet Ahluwalia,Philippe Metellus,Riccardo Soffietti
  • Publisher : Springer Nature
  • Release : 05 November 2019
GET THIS BOOKCentral Nervous System Metastases

This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and

Targeted Therapies for Lung Cancer

Targeted Therapies for Lung Cancer
  • Author : Ravi Salgia
  • Publisher : Springer
  • Release : 26 June 2019
GET THIS BOOKTargeted Therapies for Lung Cancer

This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s

Lung Cancer and Personalized Medicine

Lung Cancer and Personalized Medicine
  • Author : Aamir Ahmad,Shirish Gadgeel
  • Publisher : Springer
  • Release : 14 December 2015
GET THIS BOOKLung Cancer and Personalized Medicine

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry.

Successes and Limitations of Targeted Cancer Therapy

Successes and Limitations of Targeted Cancer Therapy
  • Author : S. Peters,R.A. Stahel
  • Publisher : Karger Medical and Scientific Publishers
  • Release : 19 February 2014
GET THIS BOOKSuccesses and Limitations of Targeted Cancer Therapy

The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy,

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher : Springer
  • Release : 15 July 2019
GET THIS BOOKCurrent Applications for Overcoming Resistance to Targeted Therapies

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians

PI3K signalling

PI3K signalling
  • Author : Klaus Okkenhaug,Martin Turner, Michael R Gold
  • Publisher : Frontiers Media SA
  • Release : 05 March 2015
GET THIS BOOKPI3K signalling

The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo